Compare Mesoblast Limited (MESO) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Utilities Select Sector SPDR Fund — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while Utilities Select Sector SPDR Fund trades at $43.66. The key difference: Mesoblast Limited is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| MESO | XLU | |
|---|---|---|
Market Cap | $2.16B | — |
Sector | Technology | — |
52-Week High | $20.96 | $47.73 |
52-Week Low | $12.88 | $41.31 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
XLU trades at $43.61, up 0.51% with a bearish technical signal from moving averages. The ETF benefits from AI-driven power demand, with recent news highlighting increased call option activity and sector momentum. Support sits at $42-43 while resistance is at $44-45. The utilities sector is gaining attention as AI data centers drive electricity consumption growth.
The outlook remains mixed with technical weakness offset by strong sector fundamentals. AI power demand creates growth opportunities, but regulatory risks and interest rate sensitivity pose challenges. The ETF's defensive income characteristics provide stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
